Next Article in Journal
Precipitation of Inorganic Salts in Mitochondrial Matrix
Previous Article in Journal
Assessing the Performance of Thin-Film Nanofiltration Membranes with Embedded Montmorillonites
Open AccessArticle

Microtube Array Membrane (MTAM)-Based Encapsulated Cell Therapy for Cancer Treatment

1
Graduate Institute of Biomedical Materials & Tissue Engineering, Taipei Medical University, Xinyi District, Taipei 11031, Taiwan
2
Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
3
The PhD Program for Translational Medicine, Taipei Medical University, Taipei 11052, Taiwan
4
Department of Pediatrics, Taipei Medical University Hospital, Taipei 11052, Taiwan
5
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan
6
International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
7
Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan
*
Author to whom correspondence should be addressed.
Co-first author.
Membranes 2020, 10(5), 80; https://doi.org/10.3390/membranes10050080
Received: 22 March 2020 / Revised: 18 April 2020 / Accepted: 20 April 2020 / Published: 26 April 2020
(This article belongs to the Special Issue Membrane Systems for Tissue Engineering 2020)
The treatment of cancer has evolved significantly in recent years with a strong focus on immunotherapy. Encapsulated Cell Therapy (ECT) for immunotherapy-based anti-cancer treatment is a unique niche within this landscape, where molecules such as signaling factors and antibodies produced from cells are encapsulated within a vehicle, with a host amount of benefits in terms of treatment efficacy and reduced side effects. However, traditional ECTs generally lie in two extremes; either a macro scale vehicle is utilized, resulting in a retrievable system but with limited diffusion and surface area, or a micro scale vehicle is utilized, resulting in a system that has excellent diffusion and surface area but is unretrievable in the event of side effects occurring, which greatly compromises the biosafety of patients. In this study we adapted our patented and novel electrospun Polysulfone (PSF) Microtube Array Membranes (MTAMs) as a ‘middle’ approach to the above dilemma, which possess excellent diffusion and surface area while being retrievable. Hybridoma cells were encapsulated within the PSF MTAMs, where they produced CEACAM6 antibodies to be used in the suppression of cancer cell line A549, MDA-MB-468 and PC 3 (control). In vitro and in vivo studies revealed excellent cell viability of hybridoma cells with continuous secretion of CEACAM6 antibodies which suppressed the MDA-MB-468 throughout the entire 21 days of experiment. Such outcome suggested that the PSF MTAMs were not only an excellent three-dimensional (3D) cell culture substrate but potentially also an excellent vehicle for the application in ECT systems. Future research needs to include a long term in vivo >6 months study before it can be used in clinical applications. View Full-Text
Keywords: encapsulated cell therapy (ECT); hybridoma; cancer; microtube array membrane (MTAM); electrospinning encapsulated cell therapy (ECT); hybridoma; cancer; microtube array membrane (MTAM); electrospinning
Show Figures

Graphical abstract

MDPI and ACS Style

Chew, C.H.; Lee, C.-W.; Huang, W.-T.; Cheng, L.-W.; Chen, A.; Cheng, T.-M.; Liu, Y.-L.; Chen, C.-C. Microtube Array Membrane (MTAM)-Based Encapsulated Cell Therapy for Cancer Treatment. Membranes 2020, 10, 80.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop